Novo Nordisk EVP: Semaglutide can double obesity business in few years

Now that the FDA has approved Novo Nordisk's semaglutide as an injection treatment for obesity, the pharmaceutical company expects to double its sales of obesity drugs.

Novo Nordisk EVP, Head of Development, Martin Holst Lange | Photo: Novo Nordisk / PR

Now that Danish pharmaceutical company Novo Nordisk has an approval from the US Food and Drug Administration (FDA) in place, Novo Nordisk is ready to launch the obesity drug Wegovy on the US market in late June.

The company is already present on the obesity market with the drug Saxenda. It expects that the new product, which uses semaglutide as an injection-based treatment, will increase sales and give Novo Nordisk access to this unexploited market.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Further reading

Related articles

Latest news

See all jobs